The U.S. Food and Drug Administration (FDA) has processed Abbreviated New Drug Application (ANDA) number ANDA205757 submitted by Pharmascience Inc. The submission was classified under a standard review priority and recorded a status of "TA" (tentative approval) on February 15, 2019. No additional details about the product or approval conditions were provided in the filing information.
This entry reflects the regulatory milestone for the generic drug application as reported by the FDA's drug approval records.
Actualités réglementaires11 sept. 2026•1 min de lecture
FDA Grants ANDA Approval for PHARMASCIENCE INC (ANDA205757)
The FDA issued a standard review tentative approval (TA) for ANDA205757 submitted by Pharmascience Inc., status dated Feb 15, 2019.
Compilé par l'équipe PharmaCountry · Source : FDA.gov
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note